Get the Stockscreener App
8.77
0.00%
0.00
After Hours:
8.77
Kalvista Pharmaceuticals Inc stock is traded at $8.77, with a volume of 381.52K.
It is up +0.00% in the last 24 hours and up +4.53% over the past month.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
See More
Previous Close:
$8.77
Open:
$8.87
24h Volume:
381.52K
Relative Volume:
1.07
Market Cap:
$433.40M
Revenue:
-
Net Income/Loss:
$-108.30M
P/E Ratio:
-2.7841
EPS:
-3.15
Net Cash Flow:
$-97.15M
1W Performance:
+0.23%
1M Performance:
+4.53%
6M Performance:
-38.54%
1Y Performance:
-40.78%
1-Day Range:
$8.71
$9.09
1-Week Range:
$8.49
$9.131
52-Week Range:
$7.30
$16.88
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
Name
Kalvista Pharmaceuticals Inc
Sector
Industry
Phone
(857) 999-0075
Address
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Compare KALV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
8.77 | 433.40M | 0 | -108.30M | -97.15M | -3.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Dec-18-24 | Initiated | BofA Securities | Buy |
| Jun-15-20 | Initiated | H.C. Wainwright | Buy |
| Jul-29-19 | Initiated | SVB Leerink | Outperform |
| Mar-20-19 | Initiated | Needham | Buy |
| Oct-30-18 | Initiated | Jefferies | Buy |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-31-17 | Initiated | BTIG Research | Buy |
View All
Kalvista Pharmaceuticals Inc Stock (KALV) Latest News
KalVista Pharmaceuticals (NASDAQ:KALV) Shares Cross Above 50-Day Moving AverageTime to Sell? - MarketBeat
KalVista Pharmaceuticals receives Orphan Drug Designation and Submits New Drug Application for Sebetralstat in Japan for Hereditary Angioedema | Events & NewsInvesting in JapanJapan External Trade Organization - jetro.go.jp
Trend Tracker for (KALV) - Stock Traders Daily
Equities Analysts Issue Forecasts for KALV FY2026 Earnings - MarketBeat
Hennion & Walsh Asset Management Inc. Makes New $634,000 Investment in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - MarketBeat
Japan grants orphan drug status to HAE treatment By Investing.com - Investing.com Canada
Japan grants orphan drug status to HAE treatment - Investing.com
KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema - Business Wire
Hennion & Walsh Asset Management Inc. Makes New Investment in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KalVista wins new Buy at BofA on potential of lead candidate - MSN
Barclays PLC Boosts Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
Barclays PLC Purchases 54,257 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - MarketBeat
KalVista Pharmaceuticals Awards Strategic Employee Stock Options Worth 111,000 Shares - StockTitan
TD Cowen Initiates Coverage of KalVista Pharmaceuticals (KALV) with Buy Recommendation - MSN
TD Cowen backs Kalvista stock as peak sales potential for sebetralstat exceeds $750MM - Investing.com Canada
KalVista Pharmaceuticals (NASDAQ:KALV) Coverage Initiated at TD Cowen - MarketBeat
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Holdings Raised by Geode Capital Management LLC - Defense World
Barclays PLC Raises Stock Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
How the (KALV) price action is used to our Advantage - Stock Traders Daily
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Purchased by State Street Corp - MarketBeat
State Street Corp Buys 515,179 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KalVista Pharmaceuticals Inc (NASDAQ: KALV) Is The Number One Stock Currently Moving. - Stocks Register
KALV Stock Touches 52-Week Low at $8.20 Amid Market Challenges - Investing.com Canada
KalVista: Potential First With Multiple Sebetralstat Regulatory Reviews In 2025 - Seeking Alpha
BofA Securities sets price target on Kalvista shares with Buy rating - Investing.com Australia
KalVista stock wins new Buy at BofA (KALV:NASDAQ) - Seeking Alpha
KalVista Pharmaceuticals (NASDAQ:KALV) Coverage Initiated at Bank of America - MarketBeat
Fmr LLC Increases Stock Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KalVista appoints new COO amid operational growth By Investing.com - Investing.com Canada
KalVista Pharmaceuticals, Inc. Appoints Jeb Ledell as Chief Operating Officer - Marketscreener.com
KalVista appoints new COO amid operational growth - Investing.com
KalVista Pharmaceuticals Appoints New COO Amid Strategic Growth - TipRanks
KalVista Pharmaceuticals appoints Jeb Ledell as COO - Seeking Alpha
KalVista Appoints Jeb Ledell as Chief Operating Officer - The Bakersfield Californian
KalVista Pharmaceuticals Taps Former AVEO Oncology Executive as New COO in Strategic Leadership Move - StockTitan
KALV Stock Touches 52-Week Low at $8.74 Amid Market Challenges - Investing.com Canada
KALV Stock Touches 52-Week Low at $8.74 Amid Market Challenges By Investing.com - Investing.com South Africa
KalVista Pharmaceuticals (NASDAQ:KALV) Given “Overweight” Rating at Cantor Fitzgerald - Defense World
KalVista CEO Benjamin Palleiko sells shares worth $74,363 By Investing.com - Investing.com Canada
KalVista CEO Benjamin Palleiko sells shares worth $74,363 - Investing.com
What is HC Wainwright's Forecast for KALV FY2029 Earnings? - MarketBeat
What is HC Wainwright’s Forecast for KALV FY2029 Earnings? - Defense World
KALVKalVista Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
KalVista Pharmaceuticals' (KALV) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
KalVista shares hold buy rating on HAE drug outlook - Investing.com
KalVista shares hold buy rating on HAE drug outlook By Investing.com - Investing.com Nigeria
KalVista Pharmaceuticals Reports Progress in HAE Treatment - TipRanks
180,000 Shares in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Purchased by Readystate Asset Management LP - MarketBeat
Kalvista Pharmaceuticals Inc Stock (KALV) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):